Origins
Our story
BetaGlue is an Italian biotech company developing next-generation nuclear therapies for solid tumors.
Born at the crossroads of biotechnology, radiochemistry, and interventional oncology, BetaGlue was founded with a single purpose: to turn nuclear science into targeted, effective treatments for cancers with limited therapeutic options.
From our headquarters in Italy, we collaborate with clinicians, scientists, and partners across Europe and the U.S. to bring innovative radiotherapeutics closer to patients who need them most.
Knowledge
Our science
Targeted nuclear medicine, redefined.
BetaGlue’s platform delivers radiation precisely where it matters most — inside the tumor.
Our lead program, YntraDose, enables interventional oncologists to deposit a therapeutic payload of beta-emitting isotopes directly within the tumor mass. This localized delivery aims to maximize tumour control while minimizing systemic exposure, making it a promising solution for pancreatic cancer and other hard-to-treat solid tumours.
Vision
Our approach
Our partnerships
Collaborating to accelerate innovation
BetaGlue partners with pharmaceutical companies, interventional radiology networks, and academic hospitals to advance clinical research, co-develop combination therapies, and scale manufacturing capabilities. Together, we aim to build the next generation of targeted radiotherapeutics that integrate seamlessly into modern cancer care.
Our hospitals
Great research centers
Our on-going early feasibility study in locally advanced pancreatic cancer is taking place in the following hospitals.
Future
Our vision
To establish BetaGlue as a reference innovator in nuclear oncology, delivering precision radiotherapeutics that transform the treatment paradigm for solid tumors. We are committed to a future where radiation is not only powerful but precise, localized, and life-changing.
